Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female gender.~* Aged between 18 and 49 years old.~* Ethnic group (Caucasian, Middle-eastern).~* Overweight (BMI 25-30 kg\^m2).~* Diagnosed with Polycystic ovary syndrome according to Rotterdam criteria (Rotterdam SHRE-ASRM Sponsored Polycystic ovary syndrome consensus workshop group, 2004).~* Diagnosed with hypovitaminosis D (serum 25(OH)D level \< 20 ng/mL).~* Inadequate dietary intake of vitamin D (\<600 IU/day or \<15μg/day).~* Physical examination being assessed and accepted by the attending physician.~* Systolic blood pressure within the normal range (90-140 mmHg).~* Diastolic blood pressure within the normal range (60-90 mmHg).~* Heart rate within the normal range (60-100 BPM).~* Oral body temperature within the normal range (35.9 - 37.6 Cᵒ).~* Normal complete blood count , Liver Function enzymes test , Aspartate Transaminase (AST) , Alanine Transaminase (ALT) and Kidney function tests , Blood Urea Nitrogen (BUN) and Serum Creatinine (SrCr).~* Participant is willing and able to give informed consent for participation in the study.~* Able and willing to comply with all study requirements.~Exclusion Criteria:~* Female participants who are pregnant, lactating or planning pregnancy during the course of the study.~* Ethnic group: non Caucasian.~* Females aged \<18 or \>49 years old.~* Underweight, normal body weight ,Body Mass Index (BMI) \< 25 kg\^m2~* Obese or morbidly obese (BMI \> 30 kg/m2)~* Diagnosis with type 1 or type 2 diabetes mellitus, hypothyroidism, hyperthyroidism, liver disease, renal dysfunction, cardiovascular diseases, androgen-secreting tumor, Cushing syndrome, congenital adrenal hyperplasia, hyperprolactinemia, and/or virilism.~* Known history or presence of food allergies or intolerance (e.g dairy products or gluten-containing foods), or any known condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs.~* History of drug or alcohol abuse, smoking of 10 cigarettes or more (or equivalent) per day.~* Participants who took medications known to affect metabolic parameters, such as metformin and corticosteroid drugs, vitamin D and calcium.~* Adequate dietary intake of vitamin D (600 IU/day or 15μg/day or more).~* Participation in another clinical or bioequivalence study within 90 days prior to the start of this study period.~* Participants with abnormal Electrocardiogram (ECG).~* Participants with any abnormal laboratory results excluding \[ 25(OH)D, Creatinine (Cr), Calcium (Ca), phosphorus (PO4), C-reactive protein(CRP) , triglyceride , High Density Lipoprotien Cholesterol (HDL-C), Low Density Lipoprotien Cholesterol (LDL-C), total cholesterol (TC)/HDL-C ratio, fasting insulin , fasting blood glucose, oral glucose tolerance test, impaired glucose tolerance, Progesterone, total testosterone, sex hormone binding globulin, parathyroid hormone and free androgen index\].

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- vitamin D3 (Biodal 50,000 IU) (Type: ACTIVE_COMPARATOR): 50,000 IU Vitamin D3 tablet given orally once weekly for 3 months
- placebo (Type: PLACEBO_COMPARATOR): Placebo tablet given orally once weekly for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).